|
FAM161A expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.8643754035329E-14 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.55031584528842E-14 |
| Normal-vs-Stage2 |
2.08444372873373E-12 |
| Normal-vs-Stage3 |
1.65290003906193E-12 |
| Normal-vs-Stage4 |
1.62525548574877E-12 |
| Stage1-vs-Stage2 |
8.486000E-01 |
| Stage1-vs-Stage3 |
5.438800E-01 |
| Stage1-vs-Stage4 |
2.128100E-02 |
| Stage2-vs-Stage3 |
8.157000E-01 |
| Stage2-vs-Stage4 |
1.384580E-01 |
| Stage3-vs-Stage4 |
1.423040E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.89848137210902E-14 |
| Normal-vs-AfricanAmerican |
1.44570000415456E-08 |
| Normal-vs-Asian |
1.35225164399344E-13 |
| Caucasian-vs-AfricanAmerican |
1.749350E-01 |
| Caucasian-vs-Asian |
7.862800E-01 |
| AfricanAmerican-vs-Asian |
2.836800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.05231403988182E-14 |
| Normal-vs-Female |
1.65500946280872E-12 |
| Male-vs-Female |
9.379800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.65290003906193E-12 |
| Normal-vs-Age(41-60Yrs) |
1.72206693349608E-12 |
| Normal-vs-Age(61-80Yrs) |
1.63136171238421E-12 |
| Normal-vs-Age(81-100Yrs) |
3.181500E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.264800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.597600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.599800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.343000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.728400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.641000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.617200E-03 |
| Classical-VS-Follicular |
8.423000E-01 |
| Classical-VS-Other |
4.838200E-01 |
| Classical-VS-Normal |
3.68371999570627E-13 |
| Tall-VS-Follicular |
2.535900E-02 |
| Tall-VS-Other |
2.066600E-01 |
| Tall-VS-Normal |
3.44169137633799E-15 |
| Follicular-VS-Other |
3.867200E-01 |
| Follicular-VS-Normal |
3.40061312442685E-12 |
| Other-VS-Normal |
8.177000E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.66444635851803E-12 |
| Normal-vs-N1 |
7.54951656745106E-15 |
| N0-vs-N1 |
1.817970E-01 |
|
|
